BNGO
Bionano Genomics, Inc. NASDAQ Listed Aug 21, 2018$1.13
+0.26%
vs $1.13
Mkt Cap $13.0M
52w Low $1.06
1.6% of range
52w High $5.50
50d MA $1.22
200d MA $1.51
P/E (TTM)
—
EV/EBITDA
—
P/B
0.1x
Debt/Equity
0.2x
ROE
-59.4%
P/FCF
-0.4x
RSI (14)
18.50
ATR (14)
$0.05
Beta
1.60
50d MA
$1.22
200d MA
$1.51
Avg Volume
159.9K
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
9540 Towne Centre Drive · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23, 2026 | AMC | -0.81 | -0.03 | +96.3% | 1.46 | -11.0% | -19.2% | +1.7% | -4.2% | +0.9% | -2.6% | — |
| Nov 13, 2025 | AMC | -1.81 | -1.59 | +12.2% | 1.47 | +5.4% | +3.4% | -1.3% | +3.3% | -0.6% | -3.2% | — |
| Aug 14, 2025 | AMC | -2.69 | -1.99 | +26.0% | 3.21 | -1.6% | -5.3% | +3.6% | +3.8% | +4.3% | +21.1% | — |
| May 14, 2025 | AMC | -3.49 | -1.15 | +67.0% | 3.74 | +15.0% | +5.1% | -3.6% | -1.3% | +0.8% | -4.0% | — |
| Mar 31, 2025 | AMC | -6.00 | -57.49 | -858.2% | 2.79 | +2.2% | +11.1% | +21.0% | -10.4% | -9.8% | -2.6% | — |
| Nov 14, 2024 | AMC | -0.21 | -19.16 | -9023.8% | 15.35 | -2.0% | -3.8% | -7.4% | -1.5% | -6.8% | +4.7% | — |
| Aug 7, 2024 | AMC | -0.42 | -14.37 | -3321.4% | 25.90 | +4.2% | -6.7% | -2.3% | +0.0% | +8.9% | -1.8% | — |
| May 8, 2024 | AMC | -0.64 | -35.93 | -5514.1% | 55.20 | +3.3% | +6.8% | -2.7% | +7.8% | +7.8% | +3.6% | — |
| Mar 5, 2024 | AMC | -0.87 | -57.49 | -6508.0% | 71.40 | -1.7% | +1.7% | -5.0% | -0.9% | -2.6% | -4.5% | — |
| Nov 8, 2023 | AMC | -44.91 | -88.62 | -97.3% | 81.60 | +0.0% | -2.2% | -2.3% | -1.5% | +9.4% | -2.1% | — |
| Aug 9, 2023 | AMC | -53.89 | -74.25 | -37.8% | 249.00 | -2.7% | -3.4% | -0.5% | -13.3% | -3.5% | -7.2% | — |
| May 9, 2023 | AMC | -53.89 | -71.86 | -33.3% | 444.00 | +0.0% | +4.9% | -3.7% | -11.4% | -0.0% | -1.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.13 | $1.14 | +0.9% | +4.4% | +2.5% | +5.8% | -1.6% | +2.4% |
| Nov 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.62 | $1.62 | +0.0% | +3.7% | +3.6% | +4.0% | +2.2% | -7.0% |
| Aug 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.04 | $3.07 | +1.0% | +3.6% | +3.8% | +4.3% | +21.1% | -3.1% |
| May 20 | Maxim Group | Upgrade | Hold → Buy | — | $3.74 | $3.91 | +4.5% | +0.8% | -4.0% | +4.1% | -1.3% | +1.3% |
| Apr 2 | Scotiabank | Maintains | Sector Perform → Sector Perform | — | $3.10 | $3.13 | +1.0% | +21.0% | -10.4% | -9.8% | -2.6% | -4.1% |
| Nov 15 | Ladenburg Thalmann | Downgrade | Buy → Neutral | — | $15.35 | $15.05 | -2.0% | -3.8% | -7.4% | -1.5% | -6.8% | +4.7% |
| May 16 | BTIG | Maintains | Buy → Buy | — | $69.00 | $69.60 | +0.9% | -3.5% | +2.7% | -5.3% | -2.8% | +5.7% |
| Mar 7 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $72.60 | $71.40 | -1.7% | -5.0% | -0.9% | -2.6% | -4.5% | +1.9% |
| Nov 13 | Maxim Group | Downgrade | Buy → Hold | — | $78.00 | $75.60 | -3.1% | -1.5% | +9.4% | -2.1% | -4.4% | +3.1% |
| Aug 10 | BTIG | Maintains | Buy → Buy | — | $249.00 | $242.40 | -2.7% | -3.4% | -0.5% | -13.3% | -3.5% | -7.2% |
| Jun 9 | BTIG | Maintains | Buy → Buy | — | $436.98 | $439.44 | +0.6% | +1.4% | +0.8% | +1.6% | -1.5% | -0.8% |
| May 18 | BTIG | Maintains | Buy → Buy | — | $420.00 | $424.80 | +1.1% | -3.0% | -1.7% | +2.5% | +3.1% | -5.6% |
| Apr 24 | BTIG | Maintains | Buy → Buy | — | $406.56 | $412.92 | +1.6% | +15.0% | -5.6% | -1.6% | -2.9% | -2.0% |
| Mar 10 | BTIG | Maintains | Buy → Buy | — | $750.00 | $726.00 | -3.2% | -4.0% | +5.0% | -1.6% | -3.2% | -4.2% |
| Feb 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $1122.00 | $1134.00 | +1.1% | -5.3% | -2.8% | -4.1% | -4.8% | -0.6% |
| Feb 5 | BTIG | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Apr 7 | BTIG | Maintains | Buy → Buy | — | $1446.00 | $1422.00 | -1.7% | -3.7% | -5.2% | -5.5% | +0.5% | +2.9% |
| Dec 4 | Roth Capital | Downgrade | Buy → Neutral | — | $298.20 | $298.20 | +0.0% | +1.0% | +5.4% | -2.4% | -1.6% | -2.5% |
No insider trades available.
8-K · 8.01
!! High
Bionano Genomics, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 24
8-K · 8.01
!! High
Bionano Genomics, Inc. -- 8-K 8.01: Material Event / Announcement
Bionano Genomics extinguished its Debentures, removing associated liens and covenants from its assets, strengthening the company's balance sheet and financial flexibility going forward.
May 28
8-K · 2.02
!! High
Bionano Genomics, Inc. -- 8-K 2.02: Earnings Results
May 13
8-K
Unknown — 8-K Filing
Bionano reported 2025 results and issued 2026 guidance, indicating management confidence in future revenue, which investors should monitor against execution to assess turnaround credibility.
Mar 23
Institutional (13F) — Top 18
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Carret Asset Management, Llc | 70,000 | $82K | Added | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 68,109 | $80K | New | Mar 2026 |
| 3 | Renaissance Technologies Llc | 48,700 | $57K | Added | Mar 2026 |
| 4 | Jane Street Group, Llc | 22,170 | $34K | New | Dec 2025 |
| 5 | Prudential Financial Inc | 28,000 | $33K | New | Mar 2026 |
| 6 | Northern Trust Corp | 20,519 | $24K | — | Mar 2026 |
| 7 | Morgan Stanley | 4,448 | $7K | Reduced | Dec 2025 |
| 8 | Wells Fargo & Company/mn | 113 | $132 | New | Mar 2026 |
| 9 | Ubs Group Ag | 16 | $19 | Reduced | Mar 2026 |
| 10 | Virtu Financial Llc | 13,751 | $16 | New | Mar 2026 |
| 11 | Bnp Paribas Financial Markets | 13 | $15 | — | Mar 2026 |
| 12 | Jpmorgan Chase & Co | 11 | $12 | — | Mar 2026 |
| 13 | Fmr Llc | 6 | $7 | New | Mar 2026 |
| 14 | Td Waterhouse Canada Inc. | 5 | $6 | Added | Mar 2026 |
| 15 | Activest Wealth Management | 3 | $5 | — | Dec 2025 |
| 16 | Medallion Wealth Advisors, Llc | 1 | $1 | — | Mar 2026 |
| 17 | Aviso Financial Inc. | 1 | $1 | — | Mar 2026 |
| 18 | Royal Bank Of Canada | 11 | — | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 3
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 51,928 | $60K | Feb 2026 |
| 2 | Fidelity Series Total Market Index Fund | 11,470 | $13K | Feb 2026 |
| 3 | Fidelity Total Market Index Fund | 2,769 | $3K | Feb 2026 |
Valuation
Market Cap
$13.0M
Enterprise Value
-$1.1M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.00x
P/B
0.14x
P/S
0.21x
P/FCF
-0.38x
EV/EBITDA
—
Shares Out
5.4M
Financials (TTM)
Revenue
$28.7M
Net Income
-$31.6M
EBITDA
-$21.7M
Free Cash Flow
-$16.3M
Op Cash Flow
-$16.3M
EPS Basic
$-4.85
EPS Diluted
$-5.80
EPS Forward
$-2.60
Gross Margin
47.0%
Op Margin
-114.0%
Net Margin
-109.9%
Balance Sheet
Total Assets
$73.6M
Total Liab.
$29.2M
Total Equity
$44.4M
Cash
$13.3M
LT Debt
$6.0M
Book Value/Sh
$8.16
Debt/Equity
0.16x
Current Ratio
1.98
Quick Ratio
1.74
Returns & Growth
ROE
-59.4%
ROA
-35.9%
ROIC
-64.6%
Rev Growth YoY
-7.4%
EPS Growth YoY
+94.5%
Price Returns
2W
+4.2%
1M
+6.9%
3M
+7.8%
6M
-33.0%
12M
-66.2%
Technicals
52W High
$5.50
52W Low
$1.06
50d MA
$1.22
200d MA
$1.51
RSI (14)
18.50
ATR (14)
$0.05
Beta
1.60
Avg Volume
160K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$46.50
High
$175.00
Low
$1.00
Median
$5.00
Data updated apr 24, 2026 10:20pm
· Source: financialmodelingprep.com